Search

everythingexperts & clinicslearnresearchcommunity

for

Search:↓

The report concludes that PCOS is mainly a condition of excess male hormones and its definition may change as new information is discovered.

Most women with excess male hormones have Polycystic Ovary Syndrome, and hormonal therapy can improve symptoms but may cause side effects.

Polycystic ovary syndrome costs the U.S. over $4 billion a year, mainly from treating related health issues.

The research found that PCOS has common genetic factors regardless of how it is diagnosed and is linked to metabolic and reproductive issues.

PCOS is a complex disorder in women that can lead to various health risks and requires personalized treatment.

Insulin resistance is a key factor in polycystic ovary syndrome, but genetics may also contribute.

Diagnosing PCOS in teenagers is challenging and should use strict criteria to avoid misdiagnosis and unnecessary worry.

High-dose dutasteride reduces PMDD symptoms by stabilizing neurosteroid levels.

The definition of Polycystic Ovary Syndrome may change with new research, and careful screening is key for managing the condition.

Obesity increases the risk of developing polycystic ovary syndrome, and weight loss can improve the condition.

Mice studies show that Protein Phosphatase 2A is crucial for cell growth, development, and disease prevention.

Amenorrhea is relatively rare and initial testing should check FSH, TSH, and prolactin levels.

Hirsutism is excessive hair growth in women often caused by polycystic ovarian syndrome, and identifying the cause is important for managing associated health risks.

Obese women with PCOS show a male-like pattern in certain fat tissue gene expressions.

The protein StAR is found in 17 different organs and can affect hair loss and brain functions, but its full role is not yet fully understood.

Melatonin improved mental health and metabolism in women with PCOS.

To diagnose Polycystic Ovarian Syndrome, two out of three signs—irregular periods, high male hormone levels, or cysts on the ovaries—are needed.

The research found that polycystic ovary syndrome (PCOS) has two distinct types, with one having more severe hormone and insulin issues.

Certain genetic variations in the SHBG gene are linked to an increased or decreased risk of PCOS in Mediterranean women.

Women with only irregular periods or excess hair have a better hormone profile than those with full PCOS, but both groups are similar, indicating a need for better PCOS diagnosis methods.

More PDCD4 is linked to obesity, insulin problems, and cell death in ovaries for those with polycystic ovary syndrome.

Hormone therapy for transgender females increases the risk of blood clots and requires careful dosing, monitoring, and lifelong management.

Curcumin may improve blood sugar levels and cholesterol in people with PCOS, but more research is needed.

Amenorrhea is when a woman doesn't have periods, with primary amenorrhea starting by age 15 or within five years of breast development, and secondary amenorrhea when periods stop for three months. It affects 3-4% of women not pregnant, breastfeeding, or in menopause, mainly due to polycystic ovary syndrome, hypothalamic amenorrhea, hyperprolactinemia, and ovarian failure.

Obesity worsens Polycystic Ovary Syndrome symptoms, and weight loss is a key treatment.

Hormonal imbalances, often indicating conditions like PCOS, are common in women with hard-to-treat acne, and a treatment approach addressing these imbalances may be needed.

Researchers found potential urine markers for polycystic ovary syndrome, including testosterone-glucuronide and 11α-hydroxyprogesterone, which may help diagnose the condition.

An mFG score of 7 or higher indicates hirsutism in Filipino women, often linked to higher free testosterone levels.

Newer low-dose oral contraceptives with less androgenic effects improve patient compliance.

Amenorrhea, or the absence of periods, should be evaluated by age 15 or within five years of early breast development, and is most commonly caused by conditions like polycystic ovary syndrome and hypothalamic amenorrhea.